EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinicogenomic Predictors of First-line Immune Checkpoint Inhibitor Outcomes in Non–Small Cell Lung Cancer: A Nationwide C CAT Cohort From Japan

Mika Iwasaki, Takahiro Ando, Koki Fujii, Kousuke Watanabe, Katsutoshi Oda, Hidenori Kage

Clinical Lung Cancer · 2026-05 · 27 (4) · 81-90.e7

DOI: 10.1016/j.cllc.2026.03.003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lung Cancer, 2026-05. Verfasst von Mika Iwasaki und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, The University of Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Konica Minolta Science and Technology Foundation, Chugai Pharmaceutical Co Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsImmune Checkpoint InhibitorsHumansFemaleMaleAgedKelch-Like ECH-Associated Protein 1JapanMiddle AgedMutationBiomarkers, TumorProto-Oncogene Proteins p21(ras)Proto-Oncogene Proteins B-rafAMP-Activated Protein Kinase KinasesPrognosisAged, 80 and overCohort Studies

Stichwörter der Autor:innen

BRAFCo-mutationComprehensive genomic profilingKEAP1KRAS

Substanzen

Immune Checkpoint InhibitorsKelch-Like ECH-Associated Protein 1KEAP1 protein, humanBiomarkers, TumorSTK11 protein, humanProto-Oncogene Proteins p21(ras)Proto-Oncogene Proteins B-rafAMP-Activated Protein Kinase KinasesKRAS protein, humanBRAF protein, human

Autor:innen und Institutionen

  • Department of Respiratory Medicine, The University of Tokyo, Tokyo, Japan.
  • Department of Respiratory Medicine, The University of Tokyo, Tokyo, Japan. Electronic address: takaando@me.com.
  • Department of Respiratory Medicine, The University of Tokyo, Tokyo, Japan; Division of Integrative Genomics, The University of Tokyo, Tokyo, Japan.
  • Division of Integrative Genomics, The University of Tokyo, Tokyo, Japan.

Förderung

  • Konica Minolta Science and Technology Foundation
  • Chugai Pharmaceutical Co Ltd

Zitieren

APA

Iwasaki, M., Ando, T., Fujii, K., Watanabe, K., Oda, K., & Kage, H. (2026). Clinicogenomic Predictors of First-line Immune Checkpoint Inhibitor Outcomes in Non–Small Cell Lung Cancer: A Nationwide C CAT Cohort From Japan. Clinical Lung Cancer, 27(4), 81-90.e7. https://doi.org/10.1016/j.cllc.2026.03.003

Vancouver

Iwasaki M, Ando T, Fujii K, Watanabe K, Oda K, Kage H. Clinicogenomic Predictors of First-line Immune Checkpoint Inhibitor Outcomes in Non–Small Cell Lung Cancer: A Nationwide C CAT Cohort From Japan. Clinical Lung Cancer. 2026;27(4):81-90.e7. doi:10.1016/j.cllc.2026.03.003

BibTeX
@article{Iwasaki2026,
  author = {Iwasaki, Mika and Ando, Takahiro and Fujii, Koki and Watanabe, Kousuke and Oda, Katsutoshi and Kage, Hidenori},
  title = {Clinicogenomic Predictors of First-line Immune Checkpoint Inhibitor Outcomes in Non–Small Cell Lung Cancer: A Nationwide C CAT Cohort From Japan},
  journal = {Clinical Lung Cancer},
  year = {2026},
  volume = {27},
  number = {4},
  pages = {81--90.e7},
  doi = {10.1016/j.cllc.2026.03.003}
}
Kostenlos starten →